Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage - Wikidata - awgldk - TriplyDB

Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage

Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage

http://www.wikidata.org/entity/Q33815032

about

Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage

http://www.wikidata.org/entity/Q33815032

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Subclinical toxicity of calcin ...... hronic kidney allograft damage

@ast

Subclinical toxicity of calcin ...... hronic kidney allograft damage

@en

type

label

Subclinical toxicity of calcin ...... hronic kidney allograft damage

@ast

Subclinical toxicity of calcin ...... hronic kidney allograft damage

@en

prefLabel

Subclinical toxicity of calcin ...... hronic kidney allograft damage

@ast

Subclinical toxicity of calcin ...... hronic kidney allograft damage

@en

P1433

Q33815032-5B819667-9E81-4C94-96B4-52AB428FD2AE

P1476

Q33815032-EC9DBAEE-34DB-45D2-A719-965F1446B3B0

P2093

Q33815032-3665EEE4-72DE-4892-A89C-B916B8F50442

Q33815032-3E7BD44B-0F50-4821-A2C6-BBAA75BD5BC1

Q33815032-4FD35C55-8A0E-48CC-9490-722F4FF796C1

Q33815032-787296A6-90CF-4A92-BB9C-57F179B8D363

Q33815032-80D53BEC-5450-4E37-987E-1812F390BC9D

Q33815032-8E054AC6-0617-4816-BE8A-822C536A6E6D

Q33815032-9F0A7CD4-0912-40BE-A697-9E231BE65A12

Q33815032-B24A1175-F7FA-4D19-A060-7241123D5C18

Q33815032-CC316B9E-29D0-43E1-A3EF-7D78198C43DF

P2860

Q33815032-19EA79F2-4F9A-4AAA-9995-235DCE7B6D5C

Q33815032-4E3267B7-BFE9-46CA-B4D6-99420D70EA3C

Q33815032-6D0BE80C-C71C-4F03-A5D5-559DE55F3579

Q33815032-836541FC-F4ED-45FB-AC4C-A48EF0273038

Q33815032-8A9C1234-A8BA-4E3E-A619-545FDE1C8139

Q33815032-963FAA8F-F0F6-4778-959B-373D92A3AE6F

Q33815032-A402F07A-06BC-4F39-9912-C7103B79E891

Q33815032-BE90962C-3AE0-42AD-9B9D-82318F144F61

Q33815032-C7BD73A5-909B-4DA8-B038-4A8A8A7380EB

Q33815032-D67D7F99-B7BB-48EE-B0F2-659E2CAC6912

P304

Q33815032-BA9F5268-3AD2-4B68-B791-9D9BCDCAAE6D

P31

Q33815032-A4726DEA-0ACE-43DE-836A-3E4EB6432258

P356

Q33815032-0A24FE16-26B4-4824-9A13-30AF4276D66C

P433

Q33815032-A429AB4B-5A07-4732-8A24-BE99ACE6825D

P478

Q33815032-4A8A8259-24F6-4237-8D80-4154D268C609

P50

Q33815032-E05DDD6C-DE85-44EF-976E-D971C7146A92

P577

Q33815032-363EF9DA-04CB-448E-BF2F-AE9A2ED4EF8B

P5875

Q33815032-84A70E77-F60E-4462-A148-21E689ED4260

P698

Q33815032-BFB27C0C-4B75-42BC-BFCE-4D6ADB98AE87

P932

Q33815032-D622C4DC-33E4-43D5-9723-38D56611D5EF

P356

J.1432-2277.2009.00995.X

P1433

Transplant International

P1476

Subclinical toxicity of calcin ...... hronic kidney allograft damage

@en

P2093

Hana Ciferská

http://www.w3.org/2001/XMLSchema#string

Josef Zadrazil

http://www.w3.org/2001/XMLSchema#string

Karel Krejcí

http://www.w3.org/2001/XMLSchema#string

Miroslav Hrubý

http://www.w3.org/2001/XMLSchema#string

Pavel Horák

http://www.w3.org/2001/XMLSchema#string

Pavel Strebl

http://www.w3.org/2001/XMLSchema#string

Petr Bachleda

http://www.w3.org/2001/XMLSchema#string

Sadek Al-Jabry

http://www.w3.org/2001/XMLSchema#string

Vladko Horcicka

http://www.w3.org/2001/XMLSchema#string

P2860

Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials.

Protocol transplant biopsies: an underutilized tool in kidney transplantation.

ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.

TGF-beta1 expression and chronic allograft nephropathy in protocol kidney graft biopsy.

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.

C4d deposition in early renal allograft protocol biopsies.

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians.

No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.

Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.

P304

364-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1432-2277.2009.00995.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38082565

http://www.w3.org/2001/XMLSchema#string

P698

19906031

http://www.w3.org/2001/XMLSchema#string

P932

2860761

http://www.w3.org/2001/XMLSchema#string